Stock Upgrades: Immunome Inc Shows Rising Relative Strength
Immunome Inc had its Relative Strength (RS) Rating upgraded from 71 to 86 Tuesday.
As you try to find the best stocks to buy and watch, keep a close on eye on relative price strength.
IBD's proprietary rating measures share price action with a 1 (worst) to 99 (best) score. The score shows how a stock's price movement over the trailing 52 weeks stacks up against all the other stocks in our database.
Decades of market research reveals that the market's biggest winners often have an RS Rating of over 80 in the early stages of their moves.
Immunome Inc is now considered extended and out of buy range after clearing a 16.87 buy point in a first-stage cup without handle. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week moving average.
Immunome Inc posted -64% EPS growth in the latest quarterly report. Sales increased 0%.
The company earns the No. 195 rank among its peers in the Medical-Biomed/Biotech industry group. Biontech Se Ads and Alkermes are also among the group's highest-rated stocks.